Celiac Disease Drug Pipeline — PatSnap Eureka
Celiac Disease Drug Pipeline: TG2 Inhibitors, IL-15 Blockade & Gluten Detoxification
Celiac disease affects approximately 1% of Western populations with a lifelong gluten-free diet as the only standard of care. Explore the emerging pharmacological pipeline — from transglutaminase inhibitors to antigen-specific immunotherapy — through the lens of global patent intelligence.
Source: PatSnap Eureka patent analysis · CeD pipeline dataset
Three Principal Molecular Targets Driving the Celiac Disease Drug Pipeline
Celiac disease (CeD) is a chronic T cell–mediated autoimmune enteropathy triggered by dietary gluten in genetically susceptible HLA-DQ2/DQ8-positive individuals. The only current standard of care is a lifelong gluten-free diet (GFD). According to WHO and multiple retrieved patent filings, the absence of disease-modifying pharmacotherapy has driven extensive IP and academic innovation across multiple mechanistic axes.
Retrieved results consistently identify tissue transglutaminase 2 (TG2) as the central enzymatic autoantigen in CeD pathogenesis. TG2 deamidates glutamine residues in partially digested gluten-derived peptides — gliadin, glutenin, hordein, secalin — converting them into high-affinity ligands for HLA-DQ2.5 and HLA-DQ8 molecules expressed on antigen-presenting cells. This deamidation step is prerequisite for activation of disease-specific CD4+ effector memory T cells in the lamina propria. Anti-tTG2 autoantibodies are established serological biomarkers of active disease.
IL-15, a cytokine overexpressed in lamina propria and intestinal epithelium of active CeD patients, is correlated with mucosal damage severity. Retrieved data from Amgen and Cephalon patents explicitly frame IL-15 dysregulation as a hallmark of CeD and refractory CeD (RCD). The NIH has catalogued IL-15 as a key driver of intraepithelial lymphocyte expansion in autoimmune enteropathies.
The HLA-DQ2.5/DQ8 antigen presentation axis is targeted by anti-HLA-DQ2.5 antibodies (Chugai Seiyaku) and antigen-specific peptide immunotherapies (Immusant, BTG International, DBV Technologies). Approximately 90% of CeD patients carry HLA-DQ2 and 5–10% carry HLA-DQ8, as cited across multiple retrieved patents. Explore the full patent landscape analysis capability on PatSnap.
Patent Activity Across the Celiac Disease Pipeline
Key data signals extracted from patent filings across therapeutic modalities and molecular targets in this dataset.
HLA Haplotype Distribution in Celiac Disease Patients
Approximately 90% of CeD patients carry HLA-DQ2; 5–10% carry HLA-DQ8 — the genetic restriction elements determining peptide immunogenicity, cited across multiple retrieved patents.
Amgen Anti-IL-15 Dosing Range (EP Filing)
The Amgen EP patent specifies anti-IL-15 antibody doses of 4–16 mg/kg in 1–6 unit doses at 1–12 week intervals, covering CeD, RCD Type I, and RCD Type II.
12 Distinct Pharmacological Approaches in the Celiac Disease Pipeline
Patent activity in this dataset spans small molecules, biologics, engineered microbes, antisense oligonucleotides, and antigen-specific tolerization strategies.
Transglutaminase 2 (TG2) Inhibitors
Dr. Falk Pharma GmbH's 2025 WO filing discloses a personalized TG2 inhibitor regimen stratified by HLA-DQ haplotype. Transcriptomic analysis in a gluten challenge model showed that 100 mg/day of TG2 inhibitor "Compound 1" suppressed virtually all gluten-induced mucosal gene expression changes. University of Debrecen covers diagnostic and therapeutic targeting of the celiac-specific transglutaminase epitope.
Preclinical → Early Clinical (inferred)Anti-IL-15 Antibody Therapy
Amgen holds the most jurisdictionally expansive anti-IL-15 IP estate — 6+ filings (US, CA, WO, AU, EP, IN, MX; 2016–2024) — covering CeD, RCD Types I & II, and NCGS. The EP filing specifies dosing at 4–16 mg/kg in 1–6 unit doses at 1–12 week intervals. Cephalon's DISC0280 antibody targets both free IL-15 and the IL-15/IL-15Rα complex, with endpoints including improved villus-to-crypt ratio and reduced IEL counts.
Clinical-stage signals (inferred)Antigen-Specific Peptide Immunotherapy
Immusant discloses a three-peptide combination (DQ2-α-I, DQ2-α-II, DQ2-α-III epitopes) across multiple jurisdictions. BTG International covers deamidated peptide epitopes including oat-derived sequences inducing IFN-γ responses. DBV Technologies' 2025 WO filing introduces epicutaneous skin-patch delivery of multi-isoform gliadin epitopes for repeated tolerization — a novel route for CeD immunotherapy.
Clinical investigation signals (Immusant)Engineered Lactococcus lactis (IL-10 + Antigen)
Intrexon Actobiotics NV / Precigen ActoBio holds the broadest multi-jurisdictional family in this dataset (WO, CA, IN, AU, US, JP, KR, CN; 2021–2023). Genetically engineered L. lactis (strain SAGX0868) chromosomally co-expresses IL-10 and deamidated HLA-DQ2/DQ8 gliadin epitopes, combining local immunosuppression with antigen-specific tolerization via oral delivery.
Advanced preclinical → Clinical (inferred)Anti-HLA-DQ2.5 Antibodies
Chugai Seiyaku Kabushiki Kaisha (IL, 2023) discloses antibodies engineered to bind specifically to HLA-DQ2.5/gluten peptide complexes — not to HLA-DQ2.5 bound to irrelevant peptides — thereby selectively blocking gluten-specific T cell activation without broad immunosuppression. This is a precision approach to the antigen presentation axis.
2023 filing — early stageJAK Inhibitors for CeD & RCD
The Regents of the University of California (WO 2022, US 2024) disclose JAK inhibitor therapy for CeD and especially RCD, framed as both anti-inflammatory and lymphoma-preventive in RCD Type II — an unmet need not addressed by TG2 inhibitors or antigen-specific therapies. May be used with or as a substitute for GFD. Explore the life sciences IP intelligence platform for deeper kinase inhibitor analysis.
WO 2022 + US 2024 active filingsBeyond Antibodies: Oligonucleotides, Nanoparticles, and Receptor Agonists
Retrieved patent data signals innovation across less conventional but mechanistically distinct therapeutic axes in celiac disease.
SMAD7 Antisense Oligonucleotide (Nogra Pharma)
Nogra Pharma's multi-jurisdictional family (WO, US, CA) covers SMAD7 antisense oligonucleotides for CeD, restoring TGF-β anti-inflammatory signaling by relieving SMAD7-mediated inhibition. Patient-level dose escalation and discontinuation criteria are described — consistent with a clinical development framework. US and CA status listed as inactive, suggesting possible discontinuation.
Tolerogenic Nanoparticles — Gliadin IMPs (Cour Pharmaceuticals)
Cour Pharmaceuticals discloses immune-modifying particles (IMPs) encapsulating gliadin antigenic material, designed to tolerize the immune system toward gliadin antigens specifically in refractory CeD. This nanoparticle-mediated antigen-specific tolerance induction approach is distinct from soluble peptide vaccines.
KIR3DL2 Targeting for Refractory CeD (Innate Pharma)
Innate Pharma (WO, 2016) discloses KIR3DL2-targeting agents specifically for RCD, where aberrant innate-like T cell populations expressing KIR3DL2 are implicated in disease progression and enteropathy-associated T-cell lymphoma (EATL) risk. This represents a targeted approach to the most severe CeD complication.
Aryl Hydrocarbon Receptor (AhR) Agonists
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (France) discloses AhR agonists, bacterial probiotics with AhR activity, and IL-22 agonists for gluten-induced gastrointestinal diseases. AhR activation is proposed to restore mucosal homeostasis and reduce inflammatory T cell activity — a direction potentially complementary to barrier-repair strategies.
Key Patent Holders by Therapeutic Cluster
Patent activity in this dataset substantially exceeds academic literature, reflecting a predominantly commercially driven innovation landscape in celiac disease.
| Assignee | Modality | Key Jurisdictions | Filing Period | Stage Signal |
|---|---|---|---|---|
| Amgen Inc. | Anti-IL-15 antibody (CeD, RCD, NCGS) | US, CA, WO, AU, EP, IN, MX | 2016–2024 | Clinical signals |
| Precigen ActoBio | Engineered L. lactis (IL-10 + gliadin antigen) | WO, CA, IN, AU, US, JP, KR, CN | 2021–2023 | Clinical signals |
| Dr. Falk Pharma GmbH | TG2 inhibitor — HLA-stratified dosing | WO | 2025 | Early clinical |
| Immusant, Inc. | Multi-epitope peptide vaccine (DQ2-α-I/II/III) | EP, NZ, HU, IN, WO, US | 2011–2016 | Clinical investigation |
| Cephalon Inc. (Teva) | Anti-IL-15 (DISC0280) — free IL-15 + IL-15/Rα complex | WO, EP | 2018–2019 | Active IP |
| DBV Technologies | Epicutaneous patch — gliadin epitope tolerization | WO | 2025 | Late preclinical |
| Chugai Seiyaku | Anti-HLA-DQ2.5 antibody (selective) | IL | 2023 | Early stage |
| Univ. of California | JAK inhibitors — CeD, RCD, lymphoma prevention | WO, US | 2022–2024 | Active filings |
Track CeD Patent Filings in Real Time
Monitor divisional filings, freedom-to-operate signals, and new assignee entries with PatSnap's IP analytics platform.
Convergent Strategies and Emerging Directions in Celiac Disease R&D
TG2 inhibition + HLA-DQ haplotype stratification is the most recent personalized medicine signal in this dataset. The Dr. Falk Pharma 2025 filing explicitly ties TG2 inhibitor dosing to HLA-DQ2/DQ8 genotype — integrating pharmacogenomics into CeD therapy selection. IP strategists should monitor divisional filings and freedom-to-operate relative to the tTG2 substrate-binding active site.
IL-10 + gliadin antigen co-delivery (Precigen ActoBio) couples local immunosuppression (IL-10) with antigen-specific tolerance induction (deamidated HLA-DQ2/DQ8 epitopes) in a single oral microbial delivery system. This combination rationale — suppression plus tolerization simultaneously — is differentiated relative to single-agent approaches. The European Patent Office database confirms multiple active family members across 8 jurisdictions.
JAK inhibition for RCD and lymphoma prevention positions JAK inhibitors as lymphoma-preventive agents in RCD Type II — an unmet need not addressed by TG2 inhibitors or antigen-specific therapies. This signals an emerging role for JAK inhibitors in the highest-risk CeD patient subgroup.
Non-invasive biomarker platforms — miRNA panels (Ospedale Pediatrico Bambino Gesù), tTG-DGP arrays (Mayo Foundation), and CCL20 after gluten challenge (Immusant) — may serve as companion diagnostics for emerging drug programs, representing potential partnership opportunities between therapeutic and diagnostic IP holders. PatSnap's customer success stories include pharma teams using this approach for companion diagnostic co-development. Developers can also access patent data programmatically via PatSnap's open API.
Development Stage Signals Across the Celiac Disease Pipeline
Inferred from patent filing breadth, dosing specificity, named strains, and trial-design methodologies in retrieved filings.
Pipeline Programs by Inferred Development Stage
Clinical-stage signals are strongest for Amgen anti-IL-15 and Precigen ActoBio L. lactis programs, based on dosing specificity and multi-jurisdictional filing breadth.
CeD Pathogenesis Cascade & Intervention Points
The therapeutic pipeline maps to five sequential steps in CeD pathogenesis, from luminal gluten exposure through adaptive immune activation and mucosal damage.
Celiac Disease Drug Pipeline — key questions answered
The only current standard of care for celiac disease is a lifelong gluten-free diet (GFD). The absence of disease-modifying pharmacotherapy has driven extensive IP and academic innovation across multiple mechanistic axes.
TG2 (tissue transglutaminase 2) deamidates glutamine residues in gliadin peptides, converting them into high-affinity ligands for HLA-DQ2.5 and HLA-DQ8 molecules. Inhibiting TG2 interrupts this early step in the pathogenic cascade before adaptive immune activation. A 100 mg daily dose of a TG2 inhibitor (Compound 1, Dr. Falk Pharma) was shown to inhibit virtually all gluten-induced transcriptomic changes in intestinal mucosa.
IL-15 is a cytokine overexpressed in lamina propria and intestinal epithelium of active celiac disease patients, correlated with mucosal damage severity. It drives intraepithelial lymphocyte (IEL) expansion and mucosal damage in celiac disease and refractory celiac disease (RCD). Amgen's anti-IL-15 antibody dosing regimens of 4–16 mg/kg administered in 1–6 unit doses at 1–12 week intervals are specified in their EP filing.
Amgen Inc. is the dominant IP holder for anti-IL-15 in celiac disease, with at least 6 patent filings across US, CA, WO, AU, EP, IN, and MX jurisdictions (2017–2024). Dr. Falk Pharma GmbH holds the most recent TG2 inhibitor filing (WO, 2025). Intrexon Actobiotics NV / Precigen ActoBio holds the broadest multi-jurisdictional family for microbial delivery (WO, CA, IN, AU, US, JP, KR, CN; 2021–2023).
Antigen-specific peptide immunotherapy uses tolerogenic peptide vaccination strategies targeting HLA-DQ2/DQ8-restricted gluten epitopes to induce immune tolerance to pathogenic gliadin peptides. Immusant discloses a three-peptide combination (DQ2-α-I, DQ2-α-II, DQ2-α-III epitopes). DBV Technologies discloses epicutaneous delivery via skin patch of a polypeptide construct comprising multiple gliadin isoform epitopes (2025 WO filing).
Refractory celiac disease (RCD, Types I and II) is the highest-risk unmet need in celiac disease. Multiple modalities specifically target this population: KIR3DL2-targeting agents (Innate Pharma) address aberrant innate T cell populations implicated in lymphoma risk; JAK inhibitors (University of California) are positioned as lymphoma-preventive agents in RCD Type II; and anti-IL-15 antibodies (Amgen, Cephalon) explicitly cover RCD in their claims.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About CeD PatentsAccelerate Your Celiac Disease Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and IP strategy across autoimmune and gastrointestinal disease pipelines.
References
- Method for personalized therapy of celiac disease — Dr. Falk Pharma GmbH, 2025, WO
- Diagnosis and treatment of gluten-induced autoimmune diseases — University of Debrecen, 2018, EP
- Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease — Amgen Inc., 2019, EP
- Anti-IL-15 antibody or antigen-binding fragment thereof, for use in the treatment of celiac disease, non-celiac gluten sensitivity and refractory celiac disease — Amgen Inc., 2024, MX
- Antibodies that specifically bind to human IL-15 and uses thereof — Cephalon Inc., 2018, WO
- Antibodies that specifically bind to human IL-15 and uses thereof — Cephalon Inc., 2019, EP
- Compositions comprising high molecular weight synthetic polymers or copolymers — Valorisation-Recherche, 2016, IL
- Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds — Valorisation-Recherche, 2007, CA
- Compositions and methods for treatment of celiac disease — Immusant Inc., 2011, EP
- Epitopes related to coeliac disease — BTG International Limited, 2010, NZ
- Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease — DBV Technologies, 2025, WO
- Immune modified particles encapsulated gliadin antigenic epitopes for treating refractory celiac disease — Cour Pharmaceuticals, 2020, IL
- Treatment of celiac disease — Intrexon Actobiotics NV / Precigen ActoBio, 2021, WO
- Treatment of celiac disease — Intrexon Actobiotics NV / Precigen ActoBio, 2022, AU
- Composition and methods of treating inflammatory and autoimmune diseases — Tiziana Life Sciences PLC, 2022, US
- Compositions and methods for treating celiac disease — The Regents of the University of California, 2022, WO
- Compositions and methods for treating celiac disease — The Regents of the University of California, 2024, US
- Treatment of celiac disease — Innate Pharma, 2016, WO
- Methods of treating celiac disease using SMAD7 inhibition — Nogra Pharma Limited, 2017, WO
- Anti-HLA-DQ2.5 antibody and its use for the treatment of celiac disease — Chugai Seiyaku Kabushiki Kaisha, 2023, IL
- Use of activators of the aryl hydrocarbon receptor for treating gluten-induced gastrointestinal diseases — Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, 2020, CA
- World Health Organization (WHO) — Autoimmune Disease and Gastrointestinal Disorders
- National Institutes of Health (NIH) — IL-15 in Autoimmune Enteropathy
- European Patent Office (EPO) — Patent Family Search
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.